RESUMO
@#navirus disease 2019 (COVID-19) in the patients younger than 18 years old infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant, and to provide a basis for determining the chest CT changes and efficacy of COVID-19 caused by Omicron virus variant in patients younger than 18 years old. Methods The clinical and imaging data of 30 cases of patients younger than 18 years old infected with COVID-19 Omicron variant, who admitted to the Third People's Hospital of Shenzhen from February 11 to March 26, 2022 were collected and retrospectively analyzed. The clinical manifestations, imaging features and dynamic changes of lesions were summarized. Results A total of 41 intrapulmonary lesions in 30 patients with COVID-19 caused by SARS-CoV-2 Omicron variant. The main manifestations were patchy or nodular ground-glass opacities and/or consolidation, with focal subpleural distribution, lesions mainly occur in the right lung (70.73%, 29/41). There were 42 lesion morphologies, with 22 (52.38%) striped shadows and 16 (38.10%) nodular shadows, with small lamellar and patchy shadows predominating. There were 36 lesion density variations, with ground glass shadows being the most common, with a total of 24 ground glass shadows (66.66%) in each lobe of the lung, and also 6 consolidation lesions (16.67%) and 6 mixed ground glass opacity and consolidation lesions (16.67%). With the progression of the disease, lesions gradually enlarged, appeared on the 2nd day (312.93 mm3), peaked on the 9th day (1 837.18 mm3). The average absorption time of the lesions was (16±3) days, and there was no significant difference between the absorption time of patchy and nodular lesions (ground glass and/or consolidation) (t=0.853, P>0.05). The lesions showed focal ground-glass opacity in the early stage, 77.78% lesions were absorbed after treatment in the late stage. Inflammatory nodules were absorbed slowly (9-19 days), without residual fibrotic changes. Conclusions The imaging manifestations of COVID-19 in patients younger than 18 years old infected with SARS-CoV-2 Omicron variant have certain characteristics, showed patchy or nodular ground glass opacities and/or consolidation, mainly distributed in the subpleural area, with small and few lesions and slow change, didn't remain fibrosis. Being familiar with its clinical and imaging manifestations can assist in early diagnosis, but confirming the diagnosis requires a combination of epidemiological history, clinical symptoms, SARS-CoV-2 nucleic acid and radiological manifestations.
RESUMO
Follicle stimulating hormone receptor is used as an imaging biomarker for the detection of ovarian cancer (OC). Inhibiton of FSHR may attenuate the carcinogenesis particularly epithelial ovarian cancer. Here we investigated FSH receptor binding inhibitor (FRBI) effects on the follicular development, to explore their impact on expressions of FSH receptor (FSHR) and estrogen receptor b (ERβ) proteins in the ovaries. 150 female mice were assigned to FRBI+FSH (COM) group, FSH group, and control group (CG). Mice in COM-1, COM-2, and COM-3 groups were intramuscularly injected with 500, 750 and 1000 μg FRBI combined with 10 IU FSH for five consecutive days. The results showed that the numbers of secondary follicles (SF) in FSH group were increased. SF numbers of three COM groups were gradually declined as the FRBI doses rose. SF numbers of COM-2 and COM-3 groups were less than the FSH group on day 20 (P <0.05). Ovarian cortex thicknesses (OCT) of COM-3 group was less than that FSH group (P <0.05). Maximum longitudinal diameter (MLD) and transverse diameter (MTD) of SFs in three COM groups were dose-dependently decreased. FSHR protein levels of COM groups were significantly decreased as compared to FSH group (P <0.05). ERβ protein levels of COM-1 and COM-2 were less than the FSH group (P <0.05). Summarily, FRBI could reduce OCT and follicle numbers, suppress follicular development, decrease expression of ovarian ERβ and FSHR protein.